Sonic Incytes was recognized as a “Company to Watch” at the 25th Annual LSBC Awards Gala, presented by Farris. This recognition underscores Sonic Incytes’ commitment to healthcare innovation and its groundbreaking product, Velacur, which is contributing to the fight against the global epidemic of non-alcoholic fatty liver disease—a condition that impacts nearly 30% of the world’s population. Sonic Incytes is poised for significant growth as the first NASH therapeutic potentially hits the market in the first quarter of 2024.
Menu
